ArticleThe Prostate2018

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Atish D Choudhury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.